title: The Triggle effect.
abstract: Dr. David Triggle is considered a pioneer in the area of ion channel pharmacology. Over the course of his career, he made a number of particularly important contributions to our understanding of dihydropyridine interactions with L-type calcium channels. He also contributed his highly sought after expertise towards the drug discovery platform of the Canadian biopharmaceutical company, NeuroMed Pharmaceuticals (subsequently Zalicus). Here we briefly highlight his contributions to the field of calcium channel pharmacology, and then provide examples of his impact on NeuroMed.
authors.affiliation: Michael Smith Laboratories and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada. Electronic address: snutch@mail.ubc.ca.
authors.forename: Terrance P
authors.initials: TP
authors.lastname: Snutch
authors.affiliation: Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Canada. Electronic address: zamponi@ucalgary.ca.
authors.forename: Gerald W
authors.initials: GW
authors.lastname: Zamponi
mesh_terms: D000818:Animals; D001955:British Columbia; D002121:Calcium Channel Blockers / Q000737:chemistry / Q000266:history; D055808:Drug Discovery / Q000266:history; D004345:Drug Industry / Q000191:economics / Q000266:history / Q000458:organization & administration; D049673:History, 20th Century; D006801:Humans; D015394:Molecular Structure; D026941:Sodium Channel Blockers / Q000266:history; D014481:United States
chemical_list: D002121:Calcium Channel Blockers; D026941:Sodium Channel Blockers
keywords: Calcium channels; Dihydropyridines; NeuroMed; Piperazines; Zalicus